Mark S. Levine insider trades: Immunovant (IMVT) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Mark reports to the SEC
Open-market buys and sales
22 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Nov 20, 2024 | IMVT | ↓ Sell | 3,650 | $25.45 | $93K | Direct | Nov 22, 2024 (2d) |
| Oct 23, 2024 | IMVT | ↓ Sell | 4,361 | $29.53 | $129K | Direct | Oct 25, 2024 (2d) |
| Oct 16, 2024 | IMVT | ↓ Sell | 2,860 | $28.79 | $82K | Direct | Oct 18, 2024 (2d) |
| Aug 21, 2024 | IMVT | ↓ Sell | 3,295 | $31.86 | $105K | Direct | Aug 23, 2024 (2d) |
| Jul 24, 2024 | IMVT | ↓ Sell | 4,015 | $27.76 | $111K | Direct | Jul 26, 2024 (2d) |
| Jul 17, 2024 | IMVT | ↓ Sell | 2,505 | $29.69 | $74K | Direct | Jul 19, 2024 (2d) |
| May 22, 2024 | IMVT | ↓ Sell | 3,242 | $29.65 | $96K | Direct | May 24, 2024 (2d) |
| Apr 24, 2024 | IMVT | ↓ Sell | 3,963 | $28.90 | $115K | Direct | Apr 26, 2024 (2d) |
| Apr 17, 2024 | IMVT | ↓ Sell | 9,827 | $29.06 | $286K | Direct | Apr 19, 2024 (2d) |
| Feb 22, 2024 | IMVT | ↓ Sell | 2,134 | $36.15 | $77K | Direct | Feb 23, 2024 (1d) |
| Jan 26, 2024 | IMVT | ↓ Sell | 3,027 | $37.92 | $115K | Direct | Jan 29, 2024 (3d) |
| Nov 22, 2023 | IMVT | ↓ Sell | 3,252 | $32.78 | $107K | Direct | Nov 24, 2023 (2d) |
| Oct 25, 2023 | IMVT | ↓ Sell | 4,107 | $34.66 | $142K | Direct | Oct 27, 2023 (2d) |
| Aug 24, 2023 | IMVT | ↓ Sell | 12,286 | $20.30 | $249K | Direct | Aug 25, 2023 (1d) |
| Jul 26, 2023 | IMVT | ↓ Sell | 3,917 | $21.63 | $85K | Direct | Jul 27, 2023 (1d) |
| Apr 25, 2023 | IMVT | ↓ Sell | 2,633 | $16.29 | $43K | Direct | Apr 26, 2023 (1d) |
| Jan 26, 2023 | IMVT | ↓ Sell | 10,156 | $18.51 | $188K | Direct | Jan 27, 2023 (1d) |
| Jul 19, 2021 | FLXN | ↓ Sell | 3,945 | $6.45 | $25K | Direct | Jul 20, 2021 (1d) |
| Jan 5, 2021 | FLXN | ↓ Sell | 6,829 | $11.13 | $76K | Direct | Jan 7, 2021 (2d) |
| Jan 3, 2019 | FLXN | ↓ Sell10b5-1 | 734 | $12.36 | $9K | Direct | Jan 4, 2019 (1d) |
| Jun 1, 2017 | NERV | ↓ Sell | 17,500 | $11.00 | $193K | Direct | Jun 5, 2017 (4d) |
| Jan 4, 2017 | NERV | ↓ Sell | 17,500 | $12.00 | $210K | Direct | Jan 6, 2017 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other IMVT insiders
Open-market trades in the last 12 months
About Mark S. Levine's insider trades
Mark S. Levine is Chief Legal Officer at Immunovant (IMVT). Since Jan 4, 2017, Mark has reported no open-market purchases and 22 sales worth $2.6M on SEC Form 4. There have been no open-market trades in the last 12 months.
1 sale (0% of the value sold) was made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so it says little about how the insider sees the stock today.
Their filings also include grants and awards (16 filings), option exercises (2 filings), shares returned to the company (1 filing), other transactions (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every IMVT insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.